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Hereditary Hemorrhagic Telangiectasia or Rendu-Osler-
Weber Disease is a rare fibrovascular dysplasia that makes 
vascular walls vulnerable to trauma and rupture, causing skin 
and mucosa bleeding. It is of dominant autosomal inheritance, 
characterized by recurrent epistaxis and telangiectasia 
on the face, hands and oral cavity; visceral arteriovenous 
malformations and positive family history. Epistaxis is 
often the first and foremost manifestation. It’s associated to 
arteriovenous malformations in several organs. There are 
possible hematologic, neurologic, pulmonary, dermatologic 
and gastrointestinal complications. Treatment is supportive 
and helps prevent complications. This study is a case report 
of a patient with this syndrome who came to the ENT 
Outpatient Ward of the Faculdade de Medicina de Marília; 
and we have done a bibliographic review of the disease’s 
etiopathogenesis, clinical manifestations and clinical-surgical 
treatment options. 
Keywords: epistaxis, rendu-osler-weber syndrome, hereditary 
hemorrhagic telangiectasia.
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INTRODUCTION
The Rendu-Osler-Weber syndrome or Hereditary 
Hemorrhagic Telangiectasia is a rare systemic fibrovascular 
dysplasia which bears, as basic defect, an alteration in the 
elastic and muscle layers of vessel walls, making them 
more vulnerable to spontaneous ruptures and injuries1,2.
The disease is autosomal dominant, although in 
about 20% of the cases, there is no family history. The 
incidence in the general population is of 1-2/100,000 and 
has a homogeneous race and gender distribution3.
Diagnosis is made according to the Curaçao Criteria: 
telangiectasia on the face, hands and oral cavity; recurrent 
epistaxis; arteriovenous malformations with visceral invol-
vement; family history. Diagnosis is confirmed upon the 
presence of at least 3 of these manifestations4.
Otorhinolaryngological manifestations are the most 
frequent, and recurrent epistaxis is the main complaint. 
Blood vessels from other regions may also be involved, 
especially those from the lungs, brain, skin and gastro-
intestinal tract1,4-6.
Treatment is of palliative nature only; there still is 
no consensus on the best treatment option. The important 
thing here is to control the disease for as long as possible. 
Options vary between anterior and posterior nasal packing 
and chemical or laser cauterization of the lesions, all the 
way to surgical treatment, such as dermoseptoplasty and 
nasal cavity obliteration through Young’s approach5,6. With 
the progress in diagnostic image tests, today it is possible 
to embolize the Maxillary, Ethmoidal or Sphenoidal arte-
ries, as well as ligation of the Maxillary or Palatine arteries 
in recurrent cases, in an attempt to contain bleeding and 
improve the patient’s anemia5.
Because of this lack of consensus regarding the best 
treatment for these cases, all cases should be described so 
as to provide a better understanding of this disease. This 
paper also aims at alerting otolaryngologists that, when 
facing a patient with recurrent epistaxis, one must suspect 
of Rendu-Osler-Weber syndrome, and perform a nasal 
fibroscopy to better diagnose this syndrome.
The present investigation reports the case of one pa-
tient with Rendu-Osler-Weber syndrome; seen at the ENT 
Ward at Faculdade de Medicina de Marília and we review 
the literature and discuss available treatment options.
CASE PRESENTATION
C.L.S., 53 years old, came to the Medical School of 
Marília Department of Otorhinolaryngology, complaining 
of mild recurrent epistaxis for 15 years, with worsening 
of the clinical Picture in the past 3 months, having had 
bleeding for more than one hour three times a day, always 
after physical exercise or sneezes. So far the patient had 
not had the need for nasal packing or other treatment.
For about 30 years he had hemangiomas spread 
throughout his body, especially in the chest, lower lip 
(Figure 1), tongue, cheek mucosa, face, fingers and nail 
bed. (Figure 2). He was also hypertensive and used cap-
topril 25mg bid and propanolol 40mg bid. He did not use 
salicylate-based drugs. His father had repetition epistaxis, 
however milder and with telangiectasia lesions on his skin 
and mucosa, without visceral lesions; and he had an 8 year 
old grandson with mild epistaxis. 
Figure 1. Lower lip Telangiectasia.
Figure 2. Fingers Telangiectasia.
During his physical exam, we noticed telangiectasia 
lesions spread throughout his chest, nails, fingers, lower 
lip, oropharynx, tongue and face. Doing anterior rhinos-
copy, we noticed hematic points on his septal mucosa and 
his left middle turbinate. There were also hematic crusts 
on his right septal mucosa. 
His chest x-ray, abdominal echography and skull 
and abdomen CT scan did not show arteriovenous malfor-
mations. Blood tests showed Hb 8.3g/dl, Ht 26.6%.
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As first treatment, we packed his nose and admitted 
him to the hospital for blood transfusion. After we removed 
the nasal packing, the epistaxis episodes relapsed, and we 
then decided to cauterize the nasal lesions through nasal 
endoscopy. Finally, we carried out right side maxillary 
artery embolization with an improvement in the intensity 
of the epistaxis episodes, however without complete remis-
sion. The patient remains under follow up in an outpatient 
basis and has been referred to Hematology, Gastroentero-
logy and Thoracic Surgery for evaluation and they found 
no pulmonary and gastrointestinal malformations. He is 
still being followed up in the hematology ward treating 
anemia and using aminocaproic acid since then. His last 
blood test showed Hb 12.4g/dL and Ht 37.4%.
BIBLIOGRAPHIC REVIEW AND DISCUSSION
 
Background
This disorder was first described in 1864, by Henry 
Gawen Sutton (1836 - 91), who reported on a disorder that 
caused epistaxis, skin telangiectasia and internal bleeding7. 
One year afterwards, Benjamin Guy Babington (1794 - 
1866) described repetition epistaxis in 5 generations of a 
family, and he was a Pioneer in describing the hereditary 
characteristic of this disease4. In 1876, John Wickham Legg 
(1843 - 1921) also described this disease, but just like 
Chiari in 1887 and Chaufffadin, in 1896, he was not able 
to differentiate this disease from hemophilia2,4.
In was only in 1896, that Louis Marie Rendu (1844 
- 1902) published a description of a 52-year-old man with 
recurrent epistaxis and telangiectasia on his face and 
torso, and lesions on his lips and soft palate. He was the 
first to suspect of nasal lesions causing epistaxis. He also 
noticed the presence of nasal bleeding in the patient’s 
mother and brother4.
In 1901, Wiliam Osler (1849 - 1919) reported three 
cases in which he described the disease’s hereditary cha-
racteristic; he was also the first to report that viscera could 
be affected4-6.
In 1907, Frederick Parkes Weber (1863 - 1962) 
reported a series of patients in whom he noticed lesions 
on their fingers, especially under the nails. It was in 1909 
that Hanes coined the term Hereditary Hemorrhagic Te-
langiectasia, however, the disease is known today by the 
eponym of Rendu-Osler-Weber’s syndrome4.
 
Genetic Heritage
It is a hereditary disorder, with dominant autoso-
mal transmission, despite the fact that about 20% of the 
cases do not have a family history - they could represent 
sporadic mutations7.
It occurs in heterozygotes with incomplete expres-
sion in some cases. The homozygote form is not com-
patible with life6. Many genes have been identified and 
implicated with the disease’s pathogenesis; however, the 
most important ones so far are the Endoglin (ENG) in chro-
mosome 9 and the type II A Activin - Como I (ACVRL-1) 
receptor, being the former associated with a variant with 
pulmonary manifestations, known as THH1 and the latter 
with a more subtle phenotype of late onset8. Both genes 
code a membrane glycoprotein that is specially expressed 
in endothelial tissue cells and make up the surface recep-
tor for the β growth factor (TGF-β), which will mediate 
vascular remodeling by affecting the extracellular matrix 
production8,9. ENG, ACVRL - 1 and TGF-β function are 
essential for angiogenesis8,9.
 
Histopathology
The histological findings once described by Jahnke 
in 1970 were an increase of submucosal vessels in intact 
endothelium, dilations of capillary, post-capillary and 
collector-type venules, with large elongated clusters of 
erythrocytes with fibrin channels in the connective tissue, 
red cells spread in the interstice around affected vessels, 
endothelial discontinuity and degeneration2,5,10. The first 
to describe these alterations was Menefee et al., in 1975, 
after a study with electron microscopy10.
The endothelial cells described were of three types: 
Normal - 90% of them; Degenerative - 7%, with a dense 
cytoplasm and less organelles present. They are less adhe-
rent to adjacent cells and develop slots between them; 
Cuboids - 3% found at random10. The basal lamina of the-
se cells were intact, sometimes doubled, even where the 
cells were degenerated or there were slots between them. 
Associated with a reduplication of the basal lamina, we 
observed frequent microfibrillae in the connective tissue, 
without other clear alterations2.
In 1990, Braverman, studied the development of 
skin telangiectasia. In a normal skin, the arterioles are 
connected to the venules through multiple capillaries 
in the papillary dermis region. These vessels come from 
other larger vessels at the skin-fat tissue junction. The post-
capillary venule’s normal ultra-structure includes the lumen 
(L), endothelial cells and two or three layers of adventitious 
cells. At first, the simple venules become dilated; however 
they are still connected to the arterioles by means of one 
or more capillaries. There is a perivascular lymphocytic 
infiltrate. In a more advanced stage, the venules and their 
branches are markedly dilated, elongated and rolled in 
the dermis. The connection arterioles are also dilated and 
such dilation makes the capillaries disappear after some 
time, causing the arteriovenous malformations (shunts 
and fistulas). The perivascular lymphocytic infiltrate is still 
present. The vessel walls loose their elastic fibers, while 
the endothelial layer, the basal membrane and the smooth 
muscles remain intact11.
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Diagnosis
Clinical diagnosis is made based on the Curaçao 
Criteria, established by the Scientific Division of the Heredi-
tary Hemorrhagic Telangiectasia International Foundation. 
It is based on: 
1- epistaxis - spontaneous and recurrent nasal 
bleeding; 
2 - telangiectasia - multiple and in characteristic sites 
(lips, oropharynx, fingers and nose) 
3 - visceral lesions - such as gastrointestinal telan-
giectasia with or without bleeding; pulmonary, hepatic, 
brain and spinal arteriovenous malformations; 
4 - family history - one first degree relative with 
Hereditary Hemorrhagic Telangiectasia4.
The multiple clinical manifestations associated with 
Hereditary Hemorrhagic Telangiectasia involve nasal, skin, 
pulmonary, cerebral and gastrointestinal tract vascular 
abnormalities5,6.
 
Clinical Manifestations
 
Nasal
Epistaxis caused by spontaneous bleeding of nasal 
mucosa telangiectasia is the most common manifestation 
of this disease; however, it does not happen to all patients, 
about 80% of them have recurrent epistaxis5. Disease se-
verity varies from severe epistaxis that requires multiple 
blood transfusions and oral iron supplementation to such 
mild manifestations that the disease is never suspected6. 
Bleeding starts around 10 year of age in some patients 
and before 21 years of age in almost all; however, they 
become more severe in later decades in two-thirds of the 
patients2.
 
Skin
The most characteristic lesion is the macular te-
langiectasia, with about 2 millimeters in diameter, which 
affect the face, lips, nose, tongue, ears, hands, upper 
body and feet2,5. They usually manifest later than epistaxis, 
and are detected around the third decade of life6. These 
lesions may bleed, however the bleeding is not clinically 
relevant.
 
Pulmonary
These are arteriovenous malformations causing 
direct communication between the pulmonary vein and 
artery by means of a thin-walled aneurism2. They are 
multiple and appear in both lungs, having a predilection 
for the lower pulmonary lobes. It is estimated that about 
60% of the persons with pulmonary arteriovenous mal-
formations have Hereditary Hemorrhagic Telangiectasia; 
however, between 15 and 33% of the persons with such 
disease have pulmonary arteriovenous malformations, 
although such incidence vary according to the specific 
gene involved9.
They produce a right-to-left shunt6. Symptoms start 
around the third or fourth decade of life and patients may, 
depending on shunt severity, present with profound dysp-
nea, fatigue, cyanosis or polycytemia6. Nonetheless, initial 
manifestations usually are sequela of neurologic lesions 
such as ischemic stroke and cerebral abscess.
They may be found as a holosystolic extracardiac 
murmur during deep inspiration or by means of image 
exams6. Chest X-Ray shows a typical mass with artery and 
vein enlargement, however, the lesions may be found in 
the posteroinferior lung region2,5. Chest CT-scan must be 
used and pulmonary angiography should be used only for 
radiological or surgical treatment planning6.
 
Cerebral
Results from pulmonary arteriovenous fistulas in 
about 60% of the cases, cerebral malformations in about 
28%, spinal chord malformation in 8% and portasystemic 
encephalopathy in 3%5,6.
They happen in between 8 and 12% of the patients 
and symptoms include: headaches, vertigo, syncope, vi-
sual and hearing disorders, focal and generalized crisis, 
obnubilation and paraparesias6.
Brain abscesses, Ischemic Strokes, Bacterial ence-
phalitis happen only in patients with right-to-left shunt and 
pulmonary arteriovenous malformations, which facilitate 
the passage of septic emboli to the brain circulation2.
 
Gastrointestinal Tract
In about 10% of the cases there is recurrent and 
small high and low gastrointestinal tract bleeding1. They 
happen mainly between the fifth or sixth decades of life 
and are caused by mucosal telangiectasia similar to those 
that happen in the oral and nasal mucosa1,4,5. In half of 
the patients, the bleeding cause may be located in the 
stomach or duodenum5. There may be larger telangiec-
tasia, angiodysplasia or less commonly, arteriovenous 
malformations2. There are reports of a greater incidence 
of duodenal ulcer; however, without clinical correlation 
with the disease12.
Liver involvement is rare. An arteriovenous malfor-
mation between the hepatic vein and artery may produce 
a left-to-right shunt, which may cause congestive heart 
failure2,5. A shunt between the hepatic and porta vein 
may cause hepatic encephalopathy and gastrointestinal 
bleeding. Malformations between the hepatic artery and 
the porta vein may cause portal hypertension with eso-
phageal varicose veins. This may be suspected when there 
is hepatomegalia or a noise over the liver. Other findings 
include a mild increase in alkaline phosphatase, γ-GT, 
and cholestasis. Ultrasound and CT scan may be used for 
diagnostic purposes 6.
Another type of liver involvement is hereditary he-
morrhagic telangiectasia cirrhosis, characterized by dilated 
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vessels surrounded by a variable amount of stroma and 
randomly distributed throughout the liver. Within these 
structures we have normal liver tissue6.
 
Treatment
Treatment is rarely necessary for skin lesions. Ho-
wever, when the telangiectasia cause cosmetic changes 
or bleed frequently, laser ablation or topic agents may 
be used5.
In pulmonary malformation, the classical treatment 
is surgery, however it is invasive and must remove as little 
as possible from the healthy pulmonary tissue around the 
malformation. The current treatment of choice is emboliza-
tion of the vessels found, although there are still no studies 
regarding the long term follow up of these patients9.
The treatment of small gastrointestinal bleedings 
may be carried out by a small combined dose of estrogen 
and progesterone that, according to Carney13, has reduced 
the need for transfusion even for some months after the 
end of treatment. Results with endoscopic laser and bi-
polar coagulation are disheartening, because the lesions, 
especially those in the small bowel, are not easily found13. 
Aminocaproic acid has been suggested as a treatment op-
tion; however its efficacy has been questioned13.
Treatment of hepatic malformations is conservati-
ve14. Experience with surgical ligation is limited and data 
on embolization, although limited, show mortality in about 
25% of the cases14.
Regarding malformations in the nervous system, 
there is no consensus as to the best treatment option - con-
servative or surgical, thus the decision depend on surgical 
risks and lethal bleeding, as well as surgeon’s experience 
and lesion location. Different treatment modes such as 
embolization and estereotactic radiosurgery with γ rays 
may be used alone or in combination6.
And finally, this study highlights epistaxis control. 
There is no standard treatment1,15. The multiple modes 
vary: anterior and posterior nasal packing, electric and/or 
chemical cauterization, vessel ligation, dermoseptoplasty, 
estrogen, hormonal therapy and, more recently, laser tre-
atment16. However, no treatment has obtained full success 
and often times it is necessary to use more than one type 
of treatment to control the epistaxis1,2,16.
Treatment aims at reducing the number of bleeding 
episodes, as well as their intensity16. It tries to reduce the 
need for blood transfusions and hospitalizations1,2. It also 
aims at improving the quality of life for those patients, who 
already suffer from constant bleeding episodes1,2.
In general, treatment with cauterization, local pres-
sure or packing is only palliative, and must be used in acute 
spells only1,2. Arterial embolization, estrogen therapy or 
laser, Young’s procedure and epithelial slice cultures are 
used as definitive treatment options in mild cases, bearing 
in mind that there is important bleeding recurrence and 
often times many treatment modalities are carried out16. 
Dermoseptoplasty and local microvascularized flaps are 
saved for the most severe cases16.
Hormonal treatment is carried out with high doses 
of estrogen, inducing nasal mucosa metaplasia towards a 
thick layer of keratinized squamous epithelium, which co-
ver eventual nasal lesions, thus protecting them from local 
trauma2. Although of proven efficacy, hormonal therapy 
has not been broadly used because of its potential side 
effects - nausea, mammary sensitivity, weight gain and 
coronary diseases6. Moreover, male patients may develop 
gynecomastia, testicular atrophy and loss of libido1,2.
Surgical treatment for this disease include: dermo-
septoplasty and nostril closure by Young’s technique16. 
Dermoseptoplasty or Saunders’s procedure was described 
by the former in 1962, and used a thin skin layer to cover 
the anterior area of the nose. Skin grafts may be harvested 
from the thigh or arm, labial mucosa or amniotic mem-
brane. Surgery consists of removing the affected mucosa 
and placing the flat over it, covering the nasal septum 
and inferior turbinates, bilaterally17. It is considered gold 
standard in the treatment1,2,6,13. Nostril closure according 
to Young’s procedure is carried out through an incision in 
the mucocutaneous junction of the nasal vestibule, which 
is taken backwards. It brings about severe side effects, 
such as oral breathing, and it is considered a last resort in 
very well selected cases17.
Microembolization is carried out using gelfoam or 
sclerosing substances from the maxillary artery under visu-
alization of angiographic films16. Brachytherapy and fibrin 
glue injection in the nasal septum and inferior turbinates 
submucosa are efficacious, however they bring about only 
temporary symptom improvement18. Treatment with ami-
nocaproic acid is not very much used; however it brings 
about significant symptoms improvement. Its side effects 
are: nausea, cramps, diarrhea, hypotension, dizziness, skin 
rash, myopathy, fatigue, rabdomyolysis, renal dysfunction 
and thrombosis16.
Laser is saved for acute bleeding spells, in an at-
tempt to contain those. In the literature we have reports 
on CO
2
, o Nd-YAG, Argon, KTP and pulsed-dye lasers. 
It is difficult to compare these lasers because of a non-
homogeneous classification in the current world medical 
literature1,2,16.
FINAL COMMENTS
Hereditary Hemorrhagic Telangiectasia is a multisys-
temic disease, first manifested by repetition epistaxis. Thus, 
it is fundamentally important that the otorhinolaryngologist 
be up-to-date in relation to the disease’s etiopathogenesis 
and treatment options, so as to perform correct diagno-
sis as well as to prevent systemic complications of this 
disease.
Thus, this paper aimed at providing an update on 
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the disease, as well as report a clinical case from the ENT 
Ward of the Medical School of Marília - Faculdade de Me-
dicina de Marília, since there are treatment options, but we 
still lack a totally satisfactory treatment modality. It is very 
important to record all cases found in order to compare 
clinical manifestations and treatment approaches so that 
in the near future we may create Standards with effective 
results and life quality improvement for the patients. 
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